We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, including phased data submission to support earlier ...

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...

Abzena, a CDMO, said it has expanded its early- and late-phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, U.K., and San Diego, CA, development and ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

HOUSTON, Dec. 3, 2025 /PRNewswire/ -- Avance Biosciences today announced the opening of its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and ...

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

CHICAGO — For patients with advanced heart failure, an injection of autologous mononuclear cells into damaged myocardia missed the primary endpoint in the sham-controlled, randomized, blinded CardiAMP ...

As the premier wellness clinic in Dubai, AEON Clinic is bridging the gap between traditional aesthetics and advanced ...

CAMBRIDGE, England and SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, announced the expansion of their early and ...